AACR 2022: Team of scientists and clinicians wins global award for transforming breast cancer treatment 04 Apr 2022 A group of UK clinical and non-clinical scientists working together across different areas of cancer research has won the AACR Team Science Award for work that has transformed treatment for many patients with breast cancer. Find out more Show/Hide
Major trial shows targeted drug improves survival in early-stage breast cancer with inherited BRCA1 or BRCA2 mutation 16 Mar 2022 The ICR strongly welcomes new findings that the targeted drug olaparib improves survival in women with high-risk, early-stage breast cancer who have inherited faults in their BRCA1 or BRCA2 genes. Find out more Show/Hide
ASCO 2021: Trial shows benefits of targeted drug against early-stage breast cancer with inherited BRCA mutation 03 Jun 2021 Women with high-risk, early-stage breast cancer who also have inherited faults in their BRCA1 or BRCA2 genes have shown a remarkable response to the targeted drug olaparib in a major clinical trial. Find out more Show/Hide
Targeting chemotherapy with genetic testing provides effective treatment for women with aggressive breast cancer 30 Apr 2018
The ICR responds to the FDA approval of olaparib for women with BRCA-mutant advanced breast cancer 12 Jan 2018